Tyra Biosciences annual stock-based compensation
2020
2021
2022
2023
2024
2025
Tyra Biosciences Stock-Based Compensation Growth & History (TYRA)
Tyra Biosciences's stock-based compensation was $28.0M for fiscal 2025.
View full Tyra Biosciences company overviewTyra Biosciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $28.0M | $5.2M | +22.83% |
| 2024 | 2024-12-31 | $22.8M | $9.3M | +68.58% |
| 2023 | 2023-12-31 | $13.5M | $2.9M | +27.74% |
| 2022 | 2022-12-31 | $10.6M | $7.7M | +266.75% |
| 2021 | 2021-12-31 | $2.9M | $2.4M | +557.63% |
| 2020 | 2020-12-31 | $439,000 | — | — |
Tyra Biosciences quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.2M | $3.9M | +60.38% |
| Q1 2026 | 2026-03-31 | $7.8M | $1.4M | +22.19% |
| Q4 2025 | 2025-12-31 | $7.6M | $925,000 | +13.80% |
| Q3 2025 | 2025-09-30 | $7.6M | $4,000 | +0.05% |
| Q2 2025 | 2025-06-30 | $6.4M | $2.0M | +44.64% |
| Q1 2025 | 2025-03-31 | $6.4M | $2.3M | +56.06% |
| Q4 2024 | 2024-12-31 | $6.7M | $2.5M | +60.11% |
| Q3 2024 | 2024-09-30 | $7.6M | $3.2M | +73.02% |
| Q2 2024 | 2024-06-30 | $4.4M | $1.9M | +74.42% |
| Q1 2024 | 2024-03-31 | $4.1M | $1.7M | +69.13% |
| Q4 2023 | 2023-12-31 | $4.2M | $1.3M | +43.90% |
| Q3 2023 | 2023-09-30 | $4.4M | $3.4M | +329.54% |
| Q2 2023 | 2023-06-30 | $2.5M | −$159,000 | −5.92% |
| Q1 2023 | 2023-03-31 | $2.4M | −$1.5M | −38.75% |
| Q4 2022 | 2022-12-31 | $2.9M | $1.0M | +55.73% |
| Q3 2022 | 2022-09-30 | $1.0M | $512,000 | +100.99% |
| Q2 2022 | 2022-06-30 | $2.7M | $2.4M | +695.27% |
| Q1 2022 | 2022-03-31 | $4.0M | $3.8M | +2182.76% |
| Q4 2021 | 2021-12-31 | $1.9M | — | — |
| Q3 2021 | 2021-09-30 | $507,000 | — | — |
| Q2 2021 | 2021-06-30 | $338,000 | — | — |
| Q1 2021 | 2021-03-31 | $174,000 | — | — |
Tyra Biosciences stock-based compensation trends
Over the last five fiscal years, Tyra Biosciences's stock-based compensation increased from $439,000 to $28.0M, a change of $27.6M. The latest reported quarter, Q2 2026, shows $10.2M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tyra Biosciences source filings ↗